A Clinical Study of Freshly Manufactured 35kDa Hyaluronan Fragment in the Treatment of Pain

• Status: Completed
• Trial end date: 2023-02-08
• Target enrollment: 0
• Participant gender: All

Summary

Local used high molecular weight Hyaluronan (HA) with high viscosity has a variety of receptors in the human body, including CD44, LYVE-1, RHAMM, HARE, Siglec-9, TLR2, CEMIP and TMEM2. Intra-articular local injection of HA has a certain degree of analgesic effect. Local injection of HA into the nerve trunk directed by ultrasound was used for the treatment of neuropathic pain. It was reported that the analgesic effect of HA is regulated by TRPV1 ion channels. This study hypothesizes that hyaluronidase cleaves HA to generate low molecular weight HA fragments HA35 with good tissue permeability, which may bind to a variety of HA receptors on the cell surface within the tissues and produce a broad-spectrum analgesic effect. In this study, 35kDa Hyaluronan fragment HA35 was prepared by mixing hyaluronidase PH20 injection and high molecular weight Hyaluronan (HA) injection at room temperature for 20 minutes. In this study, hyaluronidase injection and Hyaluronan injection were off-label used to conduct an investigator-initiated study (IIT or IIS) for the treatment of herpes zoster and shoulder, neck, back and temporal pain.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dove Medical Press Ltd
• Collaborators: Nakhia Impex LLC; The Affiliated Hospital of Qingdao University
• Treatments: Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Shoulder, neck, back and temporal pain. The course of the disease ranged from 0 to 8 months.

• Herpes zoster pain. The course of 0-2 months.

Exclusion Criteria:

• Individuals with severe spinal pathology (including fractures, inflammatory diseases and tumors)